Soft Tissue Surgical Robotics 2026: New FDA Clearances, CMS Changes, and the ASC Opportunity
- Fraol Galan
- May 29
- 5 min read
Soft-tissue surgical robotics has been effectively defined by Intuitive Surgical's da Vinci platform for more than two decades. Da Vinci is used in soft-tissue procedures across areas such as urology, thoracic surgery, and general surgery. In the U.S., most competing platforms have either focused on other categories, such as orthopedics, or remained earlier in the regulatory and commercialization pathway. Recently, the landscape has changed, and the change is seemingly structural (1).
Why Robotics, and Who It's For
Soft-tissue robotic surgery gives physicians a different way to perform minimally invasive procedures. Compared with conventional laparoscopy, robotic systems offer better visualization, finer instrument control, tremor filtering, and improved ergonomics during long cases (1-3). A 2024 randomized controlled trial found that robotic surgery lowered surgeons' ergonomic risk category from "medium" to "low" and significantly reduced cognitive strain compared with laparoscopy (3). These improvements matter because work-related musculoskeletal pain is common among laparoscopic surgeons, and reducing ergonomic strain may support surgeon comfort and career longevity (2, 3).
For patients, the typical benefits associated with robotic-assisted procedures include smaller incisions, less blood loss, shorter hospital stays, and faster return to normal activity. A 2024 overview of 165 systematic reviews found that across procedures, robotic surgery showed largely positive or neutral outcomes versus both open and laparoscopic alternatives, with evidence most clearly positive against open surgery (4).
The benefits, however, are not uniform. Robotic surgery is more expensive than conventional laparoscopy. The comparative clinical advantage over experienced laparoscopic surgeons remains debated in several procedure categories, with most trials reporting significantly longer operative times and limited demonstration of clear cost-effectiveness (4). A 2025 cohort study of nearly 738,000 Medicare beneficiaries found that bile duct injury rates after robotic-assisted cholecystectomy were roughly three times higher than after laparoscopic cholecystectomy across all patient risk strata, while separate learning-curve research has suggested hundreds of cases may be needed before robotic-assisted cholecystectomy reaches equivalent injury rates (5, 6). Outcomes depend heavily on surgeon volume and program maturity, which is part of why robotic adoption has historically concentrated in academic centers with the training infrastructure to support it.
What's Changing in the Field of Surgical Robotics
Over the past several months, the competitive landscape has expanded meaningfully. Key developments include:
Medtronic Hugo— Received FDA clearance for urologic procedures in December 2025, marking its first U.S. soft-tissue indication after years of international experience (7)
CMR Surgical Versius Plus— Secured clearance for cholecystectomy, with U.S. commercialization now under way (8)
Johnson & Johnson Ottava— Submitted to the FDA in January 2026; reported positive pivotal study results in May 2026, with clearance still pending (7)
SS Innovations SSi Mantra— Filed a 510(k), with the platform positioned around affordability and broader access (8)
Distalmotion Dexter / Moon Surgical Maestro— Positioned around outpatient and ASC workflows rather than traditional academic medical center adoption (8)
Intuitive remains the dominant player by a wide margin and continues to grow, with the company raising its 2026 procedure growth guidance earlier this year (7). What is new is not that Intuitive has weakened, but that a broader set of competitors is forming around it, with different systems aimed at different procedures, care settings, and economic buyers.
The Reimbursement Change Behind the Shift
Alongside the new entrants, Medicare expanded which procedures ambulatory surgery centers can perform and bill for, effective January 1, 2026 (7). The rule does not pay separately for robotics. Robotic assistance is generally billed as part of the underlying procedure. But the rule does open the door for more procedures to migrate from hospitals to outpatient settings. For patients, that can mean lower out-of-pocket costs and same-day discharge. For physicians, it can mean more flexibility in where they operate. For ASCs, it makes the economics of investing in a robotic platform more workable than they have been.
That creates a more favorable economic backdrop for ASCs, but it does not remove all the practical barriers to robotic adoption. Capital cost, operating room space, staffing, and case mix all still matter. The rule improves the site-of-service opportunity, but ASCs still need enough eligible cases and operational capacity to justify the investment.
Where the Market Is Moving
As these shifts occur, a key question isn’t about competing da Vinci in academic centers but rather who can build the strongest position in ASCs and community hospitals. Those settings become viable sites of service for a broader range of robotic procedures. Mordor Intelligence projects ASC-segment robotic-assisted surgery growth at roughly 16% CAGR through 2031, materially above the broader market (9).
The View from the Crow’s Nest
On the surface, the story seems straightforward: more competitors, broader access, and a market that looks different in 2026 than it did in 2024. The less straightforward story is that robotic surgery may now be starting to follow a broader shift: more procedures moving out of hospitals and into outpatient settings.
That shift has been slower for robotics. Traditional robotic systems have been expensive, space-intensive, and often built around high-volume hospital programs. As more procedures become viable in ASCs, non-hospital settings may become a larger part of the growth story for soft-tissue robotics.
ASC buyers are likely to evaluate robotics through a different lens. The decision is less about academic prestige or research partnerships and more about price, per-procedure economics, throughput, room turnover, staffing burden, and time to break even. As a result, the platforms that perform best in ASCs may be the ones built around outpatient economics: lower cost, smaller footprint, and easier workflow integration.
If you are interested in learning more, get in touch at strategy@spinnakerLS.com.
Spinnaker offers true partnership and comprehensive guidance to help leaders navigate the complexities of the Life Sciences industry and chart a path to success. From early-stage market assessment through commercial execution and ongoing lifecycle management, we deliver tailored solutions to ensure optimized practicable results.
References
Katsimperis, S., et al. "Beyond Da Vinci: Comparative Review of Next-Generation Robotic Platforms in Urologic Surgery." Journal of Clinical Medicine, 2025, 14:6775. https://doi.org/10.3390/jcm14196775
Cooper, H., et al. "A systematic review of ergonomic and muscular strain in surgeons comparing robotic to laparoscopic approaches." Journal of Robotic Surgery, 2025, 19:252. https://doi.org/10.1007/s11701-025-02401-6
Dixon, F., et al. "Robotic assisted surgery reduces ergonomic risk during minimally invasive colorectal resection: the VOLCANO randomised controlled trial." Langenbeck's Archives of Surgery, 2024, 409:142. https://doi.org/10.1007/s00423-024-03322-y
Lai, T.-J., et al. "Clinical effectiveness of robotic versus laparoscopic and open surgery: an overview of systematic reviews." BMJ Open, 2024, 14:e076750. https://doi.org/10.1136/bmjopen-2023-076750
Mullens, C.L., et al. "Patient Complexity and Bile Duct Injury After Robotic-Assisted vs Laparoscopic Cholecystectomy." JAMA Network Open, 2025, 8(3):e251705. https://doi.org/10.1001/jamanetworkopen.2025.1705
Sheetz, K.H., et al. "Learning Curve for Robotic-Assisted Cholecystectomy." JAMA Surgery, 2024. https://doi.org/10.1001/jamasurg.2024.1221
Kelly, S. "5 robotic surgery trends to watch in 2026." MedTech Dive, January 27, 2026. https://www.medtechdive.com/news/5-robotic-surgery-trends-to-watch-2026/810577/
"10 surgical robotics companies you need to know." MassDevice (2026 Surgical Robotics Special Report), March 24, 2026. https://www.massdevice.com/10-surgical-robotics-companies-you-need-to-know-2026/
Mordor Intelligence. Robotic Assisted Surgery Systems Market Size & Share Analysis — Growth Trends and Forecast (2026–2031). https://www.mordorintelligence.com/industry-reports/robotic-assisted-surgery-systems-market
